Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow Reinvestment Rate
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow Reinvestment Rate of 1.44x as of September 2025, reinvesting CN¥16.64 Million (capex CN¥16.64 Million ) from operating cash flow of CN¥11.57 Million. Explore Hubei Biocause Heilen Pharmaceutical Co. capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow Reinvestment Rate (2018–2025)
Historical reinvestment intensity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 8 annual periods. Also explore Hubei Biocause Heilen Pharmaceutical Co. asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year capital reinvestment analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For live market cap and broader valuation context, see market cap of Hubei Biocause Heilen Pharmaceutical Co..
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 8.92x | CN¥67.34 Million | CN¥7.55 Million | CN¥52.33 Million | ▼ -22.8% |
| 2024 | 11.55x | CN¥1.11 Billion | CN¥96.07 Million | CN¥164.43 Million | ▲ +661.3% |
| 2023 | 1.52x | CN¥207.94 Million | CN¥137.06 Million | CN¥186.53 Million | ▲ +48.7% |
| 2022 | 1.02x | CN¥255.82 Million | CN¥250.79 Million | CN¥75.95 Million | ▼ -49.6% |
| 2021 | 2.02x | CN¥250.71 Million | CN¥123.98 Million | CN¥21.07 Million | ▲ +326.1% |
| 2020 | 0.47x | CN¥57.74 Million | CN¥121.67 Million | CN¥13.39 Million | ▼ -38.7% |
| 2019 | 0.77x | CN¥288.37 Million | CN¥372.33 Million | CN¥32.34 Million | ▲ +135.3% |
| 2018 | 0.33x | CN¥25.08 Million | CN¥76.18 Million | CN¥25.08 Million | — |